Assay of Cefotaxime

المؤلفون

  • Salma Elkudafi Faculty of Pharmacy, Al-Fateh University of Medical Sciences, Tripoli, Libya
  • Elmusrati Faculty of Pharmacy, Al-Fateh University of Medical Sciences, Tripoli, Libya
  • Arwa Hweta Faculty of Pharmacy, Al-Fateh University of Medical Sciences, Tripoli, Libya
  • Esra Alagaly Faculty of Pharmacy, Al-Fateh University of Medical Sciences, Tripoli, Libya

DOI:

https://doi.org/10.51984/rxr3cz61

الكلمات المفتاحية:

Cefotaxime، HPLC assay، Drug quality، Antimicrobial resistance، British Pharmacopoeia

الملخص

Editorial summary prepared for the online archive; the original print article was published without an abstract.

This study assayed the active ingredient content of two brands of cefotaxime powder for parenteral use that were in use at Algala Paediatric Hospital, Tripoli, to find out whether a substandard product could be contributing to the cefotaxime resistance reported there. The content was determined by HPLC according to the British Pharmacopoeia 2001 monograph for cefotaxime injection, after optimising the methanol concentration of the mobile phase (318 ml in 1000 ml gave a retention time of about 6 minutes, a resolution of 3.6 and a symmetry factor of 1.3).

The mean content was 105.2% (SD 1.26) for the first product and 98.8% (SD 2.02) for the second, both within the pharmacopoeial limits of 90.0–110.0% of the stated amount. The authors conclude that low potency of the products does not explain the resistance, and they recommend further study of previously used products, bioavailability and the hospital’s antibiotic policy.

التنزيلات

تنزيل البيانات ليس متاحًا بعد.

المراجع

Certon et al. Resistant pathogens was identified as a serious major issue, Resistant, Microbial, Vectors, and the Host. Feb. 2002.

http: // www. medscape. com/ viewarticle /411450 retrieved on 5-April-2009.

USA National Intelligence Council report. The Global infectious Disease Threat and its Implications for the United States. Jan. 2000.

Steven Durand, executive summary of the Population Resource Center in February 2000 Technology (CISET) Working Group on Emerging and Re-Emerging Infectious Diseases. Washington.

Theodore Kelesidis et al. Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. Journal of Antimicrobial Chemotherapy 2007; 60(2): 214-236; http://jac.oxfordjournals.org/misc/ terms .shtml. retrieved on 30-March-2009.

Dora N. Akunyili. Counterfeit drugs and pharmacovigilance, the 10th pharmacovigilance. (The study of adverse drug reactions training course held at Uppsala monitoring centre Sweden), 2005.

Syhakhang I., et al. The quality of drug private pharmacies in lao PDR: a repeat study in 1997 and 1999. Pharm world Sci. 2004; 26:333-8.

Iruka N. Okeke, Abebayo Lamikanra and Robert Edelman. Socioeconomic and Behavioral Factors Leading to Acquired Bacterial Resistance in Developing Countries. Emerging infectious diseases. 1999; 5: (No. I).

Aburugaya O, Azwied. Third generation cephalosporin resistance to gram negative bacilli, Tripoli –Libya, 2006-2007.

British pharmacopeia. Publishing on the recommendation of medicines commission, London Her Majesty's stationary office, 2001.

التنزيلات

منشور

2009-01-01

إصدار

القسم

الأرشيف (النسخة الورقية)

كيفية الاقتباس

1.
Elkudafi S, Elmusrati, Hweta A, Alagaly E. Assay of Cefotaxime. J Med Sci (Sebha) [انترنت]. 1 يناير، 2009 [وثق 16 نوفمبر، 2026];8(1):41-3. موجود في: https://sebhau.edu.ly/journal/joms/article/view/5156

المؤلفات المشابهة

1-10 من 44

يمكنك أيضاً إبدأ بحثاً متقدماً عن المشابهات لهذا المؤلَّف.